• 1
    Chow JS,Chen CC,Ahsan H,Neugut AI. A population-based study of the incidence of malignant small bowel tumors: SEER, 1973-1990. Int J Epidemiol. 1996; 25: 722728.
  • 2
    Weiss NS,Yang CP. Incidence of histologic types of cancer of the small intestine. J Natl Cancer Inst. 1987; 78: 653656.
  • 3
    Jemal A,Siegel R,Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106130.
  • 4
    Howe JR,Karnell LH,Menck HR,Scott-Conner C. The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer. 1999; 86: 26932706.
  • 5
    Czaykowski P. Chemotherapy for small bowel adenocarcinoma (SBA): experience over a 10-year period at the BC Cancer Agency [abstract]. Presented at the American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium, San Francisco, California, January 22-24, 2004. Abstract 109.
  • 6
    Dabaja BS,Suki D,Pro B,Bonnen M,Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004; 101: 518526.
  • 7
    Fishman PN,Pond GR,Moore MJ, et al. Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol. 2006; 29: 225231.
  • 8
    Rochlin DB,Smart CR,Silva A. Chemotherapy of malignancies of the gastrointestinal tract. Am J Surg. 1965; 109: 4346.
  • 9
    Gibson MK,Holcroft CA,Kvols LK,Haller D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist. 2005; 10: 132137.
  • 10
    Jigyasu D,Bedikian AY,Stroehlein JR. Chemotherapy for primary adenocarcinoma of the small bowel. Cancer. 1984; 53: 2325.
  • 11
    de Gramont A,Figer A,Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18: 29382947.
  • 12
    Webb A,Cunningham D,Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997; 15: 261267.
  • 13
    Crawley C,Ross P,Norman A,Hill A,Cunningham D. The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. Br J Cancer. 1998; 78: 508510.
  • 14
    Locher C,Malka D,Boige V, et al. Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology. 2005; 69: 290294.
  • 15
    Overman MJ,Chedid S,Morris J, et al. A phase II study of capecitabine and oxaliplatin (CAPOX) in metastatic adenocarcinoma of the small bowel or ampulla of Vater [abstract]. Presented at the American Society of Clinical Oncology 2007 Gastrointestinal Cancers Symposium, Orlando, Florida, January 19-21, 2007. Abstract 139.
  • 16
    GreeneFL,PageDL,FlemingID, et al, eds. AJCC Cancer Staging Manual,6th ed. New York, NY: Springer-Verlag; 2002.
  • 17
    Abrahams NA,Halverson A,Fazio VW,Rybicki LA,Goldblum JR. Adenocarcinoma of the small bowel: a study of 37 cases with emphasis on histologic prognostic factors. Dis Colon Rectum. 2002; 45: 14961502.
  • 18
    Wu AH,Yu MC,Mack TM. Smoking, alcohol use, dietary factors and risk of small intestinal adenocarcinoma. Int J Cancer. 1997; 70: 512517.
  • 19
    Bauer RL,Palmer ML,Bauer AM,Nava HR,Douglass HOJr. Adenocarcinoma of the small intestine: 21-year review of diagnosis, treatment, and prognosis. Ann Surg Oncol. 1994; 1: 183188.
  • 20
    Frost DB,Mercado PD,Tyrell JS. Small bowel cancer: a 30-year review. Ann Surg Oncol. 1994; 1: 290295.
  • 21
    Sadeghi B,Arvieux C,Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000; 88: 358363.
  • 22
    Overman MJ,Varadhachary GR,Lin E, et al. Final response data of a phase II study of capecitabine and oxaliplatin (CAPOX) in advanced adenocarcinoma of the small bowel or ampulla of Vater [abstract]. J Clin Oncol. 2008; 26S. Abstract 4538.
  • 23
    Enzinger PC,Earle C,Zhu A, et al. Phase I dose-finding and pharmacologic study of cisplatin, irinotecan, and either capecitabine or infusional 5-FU in patients with advanced gastrointestinal malignancies [abstract]. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Hollywood, Florida, January 27-29, 2005. Abstract 28.
  • 24
    Goetz MP,Erlichman C,Windebank AJ, et al. Phase I and pharmacokinetic study of 2 different schedules of oxaliplatin, irinotecan, fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol. 2003; 21: 37613769.
  • 25
    Morgan DF,Busuttil RW. Primary adenocarcinoma of the small intestine. Am J Surg. 1977; 134: 331333.